ILiAD Biotechnologies: Funding, Investors & Team (Oct 2026)
ILiAD Biotechnologies (ILiAD) is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. ILiAD's lead candidate is BPZE1, a live-attenuated pertussis vaccine that has successfully completed a Phase 1 human clinical trial. ILiAD Biotechnologies is a registered Delaware company founded in 2012.
ILiAD Biotechnologies has raised $158M across 2 funding rounds on record, the most recent a Series D of $115M announced in Feb 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ILiAD Biotechnologies Company Profile and Key Stats
Latest funding round on record: Feb 2026.
ILiAD Biotechnologies Funding Rounds
ILiAD Biotechnologies raised $42.8M in a Series D announced in Sep 2022.
3.4 years later, a Series D of $115M was announced in Feb 2026.
ILiAD Biotechnologies Founders and Leadership Team
Contact details for the ILiAD Biotechnologies team: 1 of 1 has an email address on file.
Start 14-day free trial →ILiAD Biotechnologies Funding Compared to Other Biotechnology Startups
ILiAD Biotechnologies' latest round of $115M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ILiAD Biotechnologies in Biotechnology and New York
Companies Similar to ILiAD Biotechnologies
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
ILiAD Biotechnologies Funding FAQs
What does ILiAD Biotechnologies do?
ILiAD Biotechnologies (ILiAD) is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. ILiAD's lead candidate is BPZE1, a live-attenuated pertussis vaccine that has successfully completed a Phase 1 human clinical trial. ILiAD Biotechnologies is a registered Delaware company founded in 2012.
How much funding has ILiAD Biotechnologies raised?
ILiAD Biotechnologies has raised $158M across 2 rounds on record. The most recent is a Series D of $115M announced in Feb 2026.
When did ILiAD Biotechnologies last raise funding?
ILiAD Biotechnologies' most recent funding round on record is a Series D of $115M, announced in Feb 2026.
Who is the CEO of ILiAD Biotechnologies?
Keith Rubin is listed as CEO at ILiAD Biotechnologies.
Where is ILiAD Biotechnologies headquartered?
ILiAD Biotechnologies is based in New York, United States.
How many employees does ILiAD Biotechnologies have?
ILiAD Biotechnologies is in the 11-50 employee band.
How does ILiAD Biotechnologies' funding compare to other Biotechnology startups?
ILiAD Biotechnologies' latest round of $115M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's ILiAD Biotechnologies Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ILiAD Biotechnologies is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.